Moleculin Other Current Liab from 2010 to 2024
| MBRX Stock | USD 4.63 0.32 7.42% |
Other Current Liabilities | First Reported 2015-12-31 | Previous Quarter 1.9 M | Current Value 4.2 M | Quarterly Volatility 1.6 M |
Check Moleculin Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moleculin main balance sheet or income statement drivers, such as Interest Income of 965.1 K, Interest Expense of 2.3 M or Selling General Administrative of 9.5 K, as well as many exotic indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.93. Moleculin financial statements analysis is a perfect complement when working with Moleculin Biotech Valuation or Volatility modules.
Moleculin | Other Current Liab |
Latest Moleculin Biotech's Other Current Liab Growth Pattern
Below is the plot of the Other Current Liab of Moleculin Biotech over the last few years. It is Moleculin Biotech's Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moleculin Biotech's overall financial position and show how it may be relating to other accounts over time.
| Other Current Liab | 10 Years Trend |
|
Other Current Liab |
| Timeline |
Moleculin Other Current Liab Regression Statistics
| Arithmetic Mean | 1,303,350 | |
| Coefficient Of Variation | 112.40 | |
| Mean Deviation | 1,159,567 | |
| Median | 322,790 | |
| Standard Deviation | 1,465,020 | |
| Sample Variance | 2.1T | |
| Range | 4.5M | |
| R-Value | 0.68 | |
| Mean Square Error | 1.2T | |
| R-Squared | 0.47 | |
| Significance | 0.01 | |
| Slope | 223,500 | |
| Total Sum of Squares | 30T |
Moleculin Other Current Liab History
About Moleculin Biotech Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Moleculin Biotech income statement, its balance sheet, and the statement of cash flows. Moleculin Biotech investors use historical funamental indicators, such as Moleculin Biotech's Other Current Liab, to determine how well the company is positioned to perform in the future. Although Moleculin Biotech investors may use each financial statement separately, they are all related. The changes in Moleculin Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Moleculin Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Moleculin Biotech Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Moleculin Biotech. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Other Current Liabilities | 4.2 M | 4.4 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Moleculin Biotech Correlation against competitors. For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Complementary Tools for Moleculin Stock analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (15.15) | Return On Assets (0.39) | Return On Equity (0.76) |
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moleculin Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.